RCEL vs SYK
RCEL: A therapeutic wound care company commercializing RECELL, an autologous cell harvesting device that creates patient-derived skin cell suspension for treating burns and traumatic injuries, now expanding into a multi-product acute wound care platform. SYK: A diversified medical technology leader offering surgical equipment, orthopedic robotics, and minimally invasive neurovascular products that collectively serve over 150 million patients annually across 61 countries.
Side-by-side fundamentals
| Metric | RCEL | SYK | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $4.75 | $336.74 | |
| Market cap as of 2026-07-30 | $142M | $129.1B | |
| P/E as of 2026-07-30 | n/a | 40.36 | |
| PEG as of 2026-07-30 | n/a | 3.29 | |
| Net margin as of 2026-07-30 | -62.7% | +13.2% | SYK higher |
| Gross margin as of 2026-07-30 | +82.1% | +64.2% | RCEL higher |
| Operating margin as of 2026-07-30 | -54.6% | +19.7% | SYK higher |
| ROE as of 2026-07-30 | -337.9% | +15.1% | SYK higher |
| ROA as of 2026-07-30 | -78.9% | +7.1% | SYK higher |
| Debt / equity as of 2026-07-30 | 9.39 | 0.64 | SYK lower |
| Revenue growth (YoY) as of 2026-07-30 | +1.0% | +8.8% | SYK higher |
| Revenue CAGR (3y) SEC XBRL | +27.7% | +10.8% | RCEL higher |
| Dividend yield as of 2026-07-30 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-30 | 1.83 | 0.76 | |
| 1-year return as of 2026-07-27 close | -17.7% | -16.6% | SYK higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.